Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD ...

Exact Sciences Corp. (NASDAQ:EXAS), a leader in cancer screening and diagnostic tests with a market capitalization of $10 billion, announced clinical validation data for its OncodetectTM MRD test ...

Veracyte (VCYT) announced new data showing that its whole-genome sequencing-based platform for minimal residual disease testing detected cancer ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Instrumental data was frequently stored in manual records, spreadsheets, or site-specific servers. Users can maximize the X’Pert3 MRD XL’s performance by connecting it to the Smart Manager and ...

today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder ...

South San Francisco, California Friday, March 28, 2025, 14:00 Hrs [IST] ...

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer ...